This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
KPI Therapeutics, Inc.
Drug Names(s): Kv1.3 inhibitor
Description: KPI-190 is a topical, selective, Kv1.3 inhibitor peptide derived from the ShK family. Kv1.3 expressing, effector memory T cells (TEM cells) are present in conditions such as uveitis where they release cytokines and chemokines that lead to tissue damage in the eye. Targeting TEM lymphocytes without affecting naïve and central memory (TCM) lymphocytes, has the potential to effectively treat TEM-mediated diseases without inducing generalized immunosuppression.
Additional information available to subscribers only: